Fluorescence in situ hybridization, or FISH, uses colored probes to flag DNA changes inside plasma cells pulled from a bone marrow sample, and understanding that one core fact is where reading your results starts. The report you receive is a percentage readout of how many of those cells carry each abnormality the lab looked for, with a built-in cutoff that separates background noise from a true positive.
Those numbers carry real weight for your care, because cytogenetic findings shape your risk category, the intensity of induction therapy, and the plan for stem-cell transplant timing.
Below, the sections walk through how FISH fits into a myeloma workup, how to decode each part of your lab report, and what high-risk versus standard-risk cytogenetic findings mean for staging and treatment planning.
The Role of FISH Testing in a Myeloma Workup
Fluorescence in situ hybridization sits alongside serum protein electrophoresis (SPEP), immunofixation, free light chain assays, and the bone marrow biopsy as a core pillar of the diagnostic workup. SPEP spots the monoclonal (M-protein) spike in the gamma region of a protein graph, while immunofixation confirms the heavy chain class (IgG, IgA, IgM) and light chain type.
A skewed kappa-to-lambda free light chain ratio outside the 0.26 to 1.65 reference range adds another clue that clonal plasma cells are at work in your marrow. FISH then zooms past the protein level and reads the DNA inside the malignant cells themselves.
That DNA-level view matters because routine blood tests cannot detect a deletion on chromosome 17p or a translocation involving the IgH switch region on chromosome 14. Karyotyping, the older chromosome-spreading method, misses many of these changes because myeloma plasma cells divide slowly in culture and rarely spread their chromosomes on the slide.
FISH sidesteps that limitation by probing preserved cells directly, which is why the International Myeloma Working Group (IMWG) recommends FISH on CD138-enriched plasma cells from every newly diagnosed patient.
Why the Panel Is Standardized, Not Open-Ended
A typical myeloma FISH panel targets a defined list of abnormalities tied to prognosis: del(17p), t(4;14), t(14;16), t(14;20), t(11;14), t(6;14), 1q21 gain or amplification, 1p32 deletion, and hyperdiploidy (extra copies of odd-numbered chromosomes). Labs usually run five to seven probes in a single hybridization. Your report is not a whole-genome scan; it answers specific yes-or-no questions the clinician already had in mind.
The National Comprehensive Cancer Network (NCCN) guidelines mirror that approach and list the same probes as part of the recommended risk stratification workup.
With those recommended probes in place, it helps to know what the lab actually prints back.
Tip: Keep a photocopy or PDF of every FISH report. Future panels become far easier to compare when the probe list and the reporting lab stay the same.
Decoding the Anatomy of a FISH Lab Report
Each row on the report names a probe set, lists the result, and prints a percentage. A probe is a short strand of fluorescent DNA designed to latch onto the chromosome region in question. When the probe binds, a colored dot appears under the microscope; the lab tech counts cells with the dot and divides by the total scored (usually 100 to 200 plasma cells) to give the percentage you see.
The most important column is the cutoff column. For deletions and gains the lab applies a threshold near 10 percent of cells; for translocations the cutoff is tighter, usually 1 to 2 percent because balanced rearrangements are unlikely to occur by chance. A result below the cutoff is reported as negative or within normal limits. Anything above the cutoff gets flagged as positive, with the exact percentage printed beside it.
What the Other Columns Tell You
Look for sample quality indicators, probe counts, and control gene results. A sample is considered adequate when the lab can score at least 100 plasma cells identified by a CD138 marker or by light-chain restriction. Control probes confirm that the hybridization chemistry worked on your specific sample. If a probe fails quality control, the lab prints a comment such as “insufficient signal” or “indeterminate,” and your hematologist may request a repeat draw rather than guess at the result.
| Report Element | What It Shows | Why It Matters |
|---|---|---|
| Probe name | The chromosome region targeted (e.g., 17p13.1) | Tells you exactly which gene neighborhood was checked |
| Result | Positive, negative, or indeterminate | Whether the abnormality was detected above the cutoff |
| Percentage of cells | Number out of 100 to 200 scored cells carrying the abnormality | Higher burden can shift your risk category |
| Cutoff | Lab-defined threshold (typically 10% for deletions, 1 to 2% for translocations) | The line between background noise and a real finding |
| Sample quality | Number of plasma cells scored, viability, control gene result | Confirms the result is trustworthy |
Standard-Risk Versus High-Risk Cytogenetic Findings
Hyperdiploidy, defined as extra odd-numbered chromosomes (3, 5, 7, 9, 11, 15, 19, 21), is generally favorable. So is an isolated t(11;14), a translocation that brings the CCND1 gene under the immunoglobulin heavy chain promoter and drives cyclin D1 overexpression. Neither finding by itself forces a change to first-line induction, though t(11;14) has gained attention as a marker that may predict response to BCL2 inhibitors in your regimen.
High-risk markers tell a different story. Deletion of the short arm of chromosome 17 removes one copy of TP53, the tumor suppressor that normally coordinates DNA damage response. Translocations t(4;14) and t(14;16) reposition MMSET or MAF genes next to the IgH enhancer, rewiring the cell’s growth program. Gain or amplification of the long arm of chromosome 1 (1q21) adds copies of CKS1B and other genes that accelerate cell-cycle progression.
The IMWG lists del(17p), t(4;14), t(14;16), t(14;20), and 1q21 gain or amplification as the core high-risk lesions, and the Multiple Myeloma Research Foundation (MMRF) tracks the same set in its patient education materials.
Why Co-Occurring Abnormalities Push Risk Higher
Risk in myeloma is additive rather than all-or-nothing. A single high-risk lesion roughly doubles the hazard of early progression; two or three stacked abnormalities can shorten your remission by several years. Del(17p) plus 1q21 gain carries a worse outlook than del(17p) alone, and t(4;14) layered on top of hyperdiploidy erodes much of the favorable signal. That’s why an otherwise low-stage patient with two high-risk markers may still receive intensified induction.
Because that interaction reshapes how oncologists interpret the disease, it directly informs both the stage assigned and the prognosis communicated.
| Cytogenetic Finding | Typical Risk Category | Common Clinical Implication |
|---|---|---|
| Hyperdiploidy | Standard | Conventional triplet induction often appropriate |
| Isolated t(11;14) | Standard | Standard induction; may inform later-line choices |
| t(4;14) | High | Often prompts quadruplet induction and early transplant |
| t(14;16) or t(14;20) | High | Aggressive regimen, close monitoring |
| del(17p) | High | Quadruplet therapy, transplant referral, clinical trial discussion |
| 1q21 gain or amplification | High | Treated as adverse; intensity depends on co-abnormalities |
Connecting FISH Results to Staging and Prognosis
FISH findings feed directly into the Revised International Staging System (R-ISS) and its newer iteration R2-ISS. Stage I through III traditionally reflect beta-2 microglobulin and albumin levels; cytogenetic data and serum LDH are layered on top to sharpen your prognosis. A patient with ISS stage II disease (beta-2 microglobulin between 3.5 and 5.5 mg/L) but del(17p) automatically lands in R-ISS stage III, because that single deletion shifts the expected survival curve.
The numbers matter for your day-to-day planning, not just textbook classification. Five-year overall survival for R-ISS stage I patients runs roughly 82 percent, while stage III hovers near 40 percent in published IMWG validation cohorts. Within stage III, patients carrying del(17p) or two high-risk lesions face shorter remissions than those whose stage III status comes only from elevated beta-2 microglobulin. Staging is a starting estimate, not a sentence.
Serial Bone Marrow Studies and Clonal Evolution
Cytogenetics in myeloma are not always static. At relapse, roughly 20 percent of patients acquire new abnormalities that were not present at diagnosis, a process called clonal evolution. A repeat bone marrow with FISH is often ordered when disease behavior changes, when M-protein rises despite therapy, or when the free light chain ratio climbs outside the reference window.
The International Myeloma Foundation (IMF) advises patients to ask about repeat testing whenever a treatment plateau is reached and the disease later begins to move again.
Translating Results Into Treatment and Monitoring Decisions
Standard-risk findings typically allow conventional triplet induction built on a proteasome inhibitor, an immunomodulatory drug, and a steroid. A high-risk FISH panel pushes the regimen toward a quadruplet that adds a monoclonal antibody such as daratumumab, with earlier referral for autologous stem-cell transplant. Your maintenance therapy may also be intensified, and clinical trial enrollment is often discussed when del(17p) or double-hit biology is present.
Monitoring strategy shifts alongside your baseline report. A rising percentage of abnormal cells on a follow-up FISH panel can signal clonal evolution and emerging therapy resistance. Pairing those FISH trends with serial M-protein, free light chain ratio, and minimal residual disease (MRD) testing builds a fuller response picture.
MRD-negative status, meaning no clonal plasma cells detected at a sensitivity of one in 100,000 cells by next-generation flow or one in 1,000,000 by clonoSEQ-style sequencing, is now recognized by the IMWG as the deepest measurable response, but it sits on top of, not in place of, your cytogenetic baseline.
Since those decisions rest on a shared understanding, preparing a few pointed questions before the next visit makes the conversation far more productive.
Three Practical Tips for the Monitoring Phase
- Track percentages, not just labels. A t(4;14) that climbs from 15 percent to 60 percent of cells suggests clonal expansion even before M-protein moves.
- Pair FISH with protein markers. M-protein by SPEP, urinary light chains (Bence Jones proteins) by UPEP, and the free light chain ratio each add a different layer of information.
- Request MRD testing when relevant. Flow cytometry or sequencing-based MRD assays can confirm depth of response once M-protein becomes undetectable.
Questions Worth Bringing to Your Hematologist
Bring a printed copy of the FISH report to your appointment and walk through it line by line. Ask which specific abnormalities were detected, the percentage of cells carrying each one, and whether the findings place you in the standard-risk or high-risk category as defined by IMWG criteria. Clarify how those results shape your induction regimen, transplant timing, and maintenance plan.
If del(17p) or 1q21 amplification is present, ask whether a clinical trial or intensified quadruplet therapy is appropriate.
Discuss whether repeat FISH is planned and how the results will be tracked alongside your blood and urine markers. Ask for the cutoff values the lab used so you can compare future panels against the same thresholds. Finally, request the full report in your patient portal so you can re-read it at home and share it with a second-opinion specialist if you choose one.
Tip: If anything on the report is unclear, ask the nurse navigator or hematologist to circle the percentage column and the risk category in pen. Visual anchoring helps you remember what each number means at the next visit.
The Bottom Line
A FISH report is a percentage-driven snapshot of the DNA inside your plasma cells, and those percentages directly determine whether your myeloma is classified as standard-risk or high-risk. Learning to read the probe names, cutoffs, and quality indicators turns the document from a wall of jargon into a planning tool that you and your care team can act on together.
FAQ
What does a normal FISH test result look like for multiple myeloma?
A normal result prints “negative” or “not detected” beside each probe in the panel, with percentages below the lab cutoff (usually 10 percent for deletions and 1 to 2 percent for translocations). It means none of the high-risk or standard-risk abnormalities the panel screens for were found above the noise threshold in your sample.
Which chromosome abnormalities detected by FISH indicate high-risk myeloma?
The IMWG defines del(17p), t(4;14), t(14;16), t(14;20), and 1q21 gain or amplification as high-risk cytogenetic abnormalities. Any one of these typically shifts your management toward more aggressive induction and earlier transplant consideration.
How accurate is FISH testing compared to karyotyping in multiple myeloma?
FISH is more sensitive than conventional karyotyping for myeloma because it probes non-dividing plasma cells directly. Karyotyping misses many abnormalities because the malignant cells divide poorly in culture, while FISH on CD138-enriched plasma cells detects cryptic translocations and small deletions that karyotyping cannot resolve.
Can FISH test results change myeloma treatment decisions?
Yes. A high-risk FISH result often pushes treatment from a triplet to a quadruplet regimen, accelerates transplant timing, and may open the door to clinical trial enrollment. A standard-risk result can spare you from overtreatment and support a more conventional induction path.
How soon after a FISH test do multiple myeloma results come back?
Most reference labs return FISH results within 5 to 10 business days after the bone marrow sample arrives. Turnaround can stretch to two weeks if a probe fails quality control and a redraw or repeat hybridization is needed.
What is the difference between FISH and FISH-MRD testing in myeloma?
Diagnostic FISH looks for high-risk cytogenetic abnormalities in plasma cells at diagnosis or relapse. FISH-based MRD uses a similar probe chemistry but applies it after therapy to detect whether any abnormal cells remain at very low levels. Both rely on the same fluorescent probe technology, but the goal and the sensitivity threshold are different.
